Neoadjuvant melanoma

Nearly half of stage III melanoma patients treated with surgery and adjuvant immunotherapy recur, progress or die within twelve months.¹

Patients reaching a complete pathologic response have a 95.4% event-free survival at one year; those who do not, 57%.²

1 in 2¹

stage III patients recur, progress or die within twelve months

95.4%²

event-free survival at one year with a complete pathologic response

57%²

for those without one

Cytokines are the most potent immunotherapy ever discovered and the least usable. Solving delivery makes the whole class viable again.